Drugs / GRWD5769
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06923761 | May 2023 → Apr 2027 expected | cancer | Grey Wolf Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRWD5769 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06923761 ↗ |
| Route | Intravenous | “Module 2 (GRWD5769 in combination with cemiplimab, administered IV)” NCT06923761 ↗ |